OrtelT.L., MercerM.C., ThamesE.H., MooreK.D., LawsonJ.H.Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg.2001; 233(1): 88–96.
2.
SarfatiM.R., DiLorenzoD.J., KraissL.W., GaltS.W.Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg.2004; 18(3): 349–351.
3.
KirkebyK.M., AronowtizP.Acquired factor V inhibitor: a common and avoidable complication of topical bovine thrombin application [letter]. Am J Med.2005; 118(7): 805.
4.
CrowS.S., SullivanV.V., AysolaA.E.Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg.2007; 83(4): 1547–1549.
5.
SavageW.J., KicklerT.S., TakemotoC.M.Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure. Pediatr Blood Cancer.2007; 49(7)): 1025–1029.
6.
PoyntonA.R., NelsonM.C., McCanceS.E., LevineR.L., O'LearyP.F.Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine.2003; 28(12): E221–E223.
7.
NeschisD.G., HeymanM.R., CheanvechaiV., BenjaminM.E., FlinnW.R.Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin. J Vasc Surg.2002; 35(2): 400–402.
8.
LawsonJ.H., LynnK.A., VanmatreR.M.Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg.2005; 79(3): 1037–1038.
9.
StreiffM.B., NessP.M.Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion.2002; 42(1): 18–26.
10.
Thrombin-JMI [package insert].Bristol, TN: King Pharmaceuticals, Inc.; November 2007.
TerrabA., PawlakD., SpaayP., HoppensteadtD., FareedJ.Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost.2008; 14(2): 135–140.
13.
SchoeneckerJ.G., JohnsonR.K., FieldsR.C.Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg.2003; 197(4): 580–590.
